Ixabepilone

Drug Profile

Ixabepilone

Alternative Names: Azaepothilone B; BMS-247550; Epothilone B analogue; Ixempra; Patupilone analogue

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator GBF
  • Developer Bristol-Myers Squibb; R-Pharm; Yale University
  • Class Antineoplastics; Epothilones; Macrolides; Small molecules
  • Mechanism of Action Cell cycle inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Ovarian cancer
  • No development reported Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer
  • Discontinued Cancer; Endometrial cancer; Prostate cancer

Most Recent Events

  • 03 Apr 2017 Phase-II clinical trials in Ovarian cancer (In the elderly, Metastatic disease, Second-line therapy or greater, In adults, Combination therapy) in USA (IV) (NCT03093155)
  • 03 Apr 2017 Phase-II clinical trials in Ovarian cancer (Monotherapy, Metastatic disease, Second-line therapy or greater, In adults, In the elderly) in USA (IV) (NCT03093155)
  • 17 Aug 2015 R-Pharm acquires ixabepilone from Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top